News

ODU breaks ground on $184M biosciences building

Old Dominion University on Monday broke ground on the biggest capital project in the 95-year-old university’s history — a new biological sciences building.

The planned five-story, 162,586 square-foot building will be located on ‘s campus in , near the university’s Oceanography and Mills Godwin Life Sciences buildings.

ODU spokesperson Jonah Ross Grinkewitz said the $184 million project is funded by a state bond issue and will house classrooms, teaching laboratories, a 120-seat lecture hall and other student support spaces. State and campus leaders, and community members gathered Monday to commemorate the .

“Today would not be possible without significant support from the Commonwealth of Virginia,” said President Brian O. Hemphill in a Monday statement. “With the leadership and action of Gov. Youngkin and the General Assembly, a $184 million investment has been made in Old Dominion University, specifically our students, representing the largest in the history of our institution in terms of both scope and size.”

The building is meant to support faculty and student research in biomedical and ecological areas. As part of the project, the Arthur and Phyllis Kaplan Orchid Conservatory will be relocated within the biological sciences building with an added water feature and a two-story tropical display house. The exterior design incorporates an existing pond and features a terraced seating area.

A team that includes VMDO Architects, Ballinger and O’Shea Wilson Site Works designed the building. Newport News-based will serve as the project’s general contractor.

The building is expected to be ready for use in spring 2028.

Virginia Secretary of Education Aimee Guidera said the building embodies the ODU’s mission of being a “forward-focused, innovative and entrepreneurial research university.

“The pioneering biological research conducted at this state-of-the-art research and development hub will prepare students to succeed in their lives and careers beyond graduation,” Guidera added in a statement.

Read more here.

 

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business